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Case history
A 29 years old male presented to our hospital with a three 
week history of  left foot and left knee swelling. This was 
followed a week later by lower back, hip and bilateral lower 
chest pains. In the third week of  illness, his walking became 
impaired due to his limb pain, and due to increasing difficulty 
in fully extending his neck. These symptoms were worse in 
the early morning, and initially eased over a few hours. This 
deteriorated, and by the time he presented to hospital he 
was confined to bed for most of  the day.  There was no 
preceding history of  rash, dyspnoea, cough or gastrointestinal 
disturbance. Vision was subjectively normal, and he reported 
no ocular problems. Constitutionally, he was well with no 
weight loss or night sweats.
He had presented in a similar manner on a number of  
occasions within the preceding seven years. These episodes 
were typically characterised by lower back pain, large joint 
swelling and stiffness. Some appeared to have been self  
limiting, while during others he had been variously treated 
with non-steroidal anti inflammatory agents, and systemic 
corticosteroids. The last episode was eighteen months 
prior to presentation: at that time there was very little chest 
involvement and completely no neck involvement. Although 
between periods of  illness he was able to return to work, 
there appeared to be a progressive decline in function. He 
was worried about his job security as a builder and subsistence 
farmer.
Past medical history was unremarkable, with no previous 
surgery or hospital admission. He had never smoked and did 
not drink alcohol. 
He had attended school for six years and had three well 
children. A single family member (his paternal uncle) 
complained of  recurrent joint pain and swelling of  both 
knees, but had never sought medical attention for this. 
On examination he held his neck in mid flexion which 
minimised otherwise severe pain. His vital signs were: blood 
pressure: 110/76mmHg; pulse 96/min, regular and full 
volume; temperature 36OC; respiratory rate 18/min. There 
was no evidence of  anaemia, lymphadenopathy or mucosal 
lesions. His nutritional status was poor (BMI 16.0).
In the lumbar spine, movements in all planes were reduced. 
For comfort, he used pillows to support his thoracic spine 
whilst lying. Both knees were swollen and felt warm. On the 
left, there was limited flexion, and full extension was not 
possible. There was similar, though less severe limitation 
on the right. There were no clinically detectable effusions 
by patella tap, no joint line tenderness, and no crepitus 
on passive movement. The hips and left ankle were also 
affected by limited range of  active movement. There was an 
effusion of  the right index metacarpophalyngeal joint, but 
no involvement of  any other small joints.
Chest expansion was bilaterally subjectively reduced. 
Otherwise, clinical examination of  the chest and abdomen 
was normal. Fingernails were normal, there were no 
peripheral stigmata of  infective endocarditis. He was not 
confused, and had no neurological deficit in his limbs.
Radiography of  the cervical spine was normal. The lumbar 
spine demonstrated fusion of  the spinous processes of  L2-
L4. There was evidence of  inflammatory change of  the 
sacroiliac joints bilaterally, with loss of  joint space (see Figure 
1). No other radiographs were taken. He was HIV negative. 
Full blood count showed: Hb 10.7, WCC 10.3, Pl 328. White 
cell differential was unavailable.
He was treated with oral prednisolone 40mg/day and 
aspirin 600mg qid for his joint disease. Further analgesia was 
given in the form of  oramorph to allow early mobilisation. 
Additionally, omeprazole was added as prophylaxis against 
peptic ulceration.
Over the course of  the next week, he became independently 
mobile, and was discharged home with instructions to taper 
his prednisolone to 10mg. He was next seen six weeks later 
in clinic, having run out of  medication and been unable to 
travel earlier due to lack of  funds. At this point, although 
there was no joint swelling, back pain was considerable.
Spirometry performed as an outpatient showed: FEV1 
1.78 (60% of  predicted), FVC 1.85 (53% predicted), PEFR 
7.77 (92% predicted), FEV1/FVC 0.96. Lung volumes and 
gas transfer were not available. We were unable to test for 
rheumatoid factor or other immunological markers.
Figure 1: Plain AP radiograph of the sacroiliac joints and lumbar spine
Questions
1.What is the likely diagnosis, and what are other 
possibilities?
2.How could you account for the spirometry 
findings?
3.What would be the treatment of choice?
Discussion
Our patient demonstrated a slowly progressive inflammatory 
disorder of  the joints, starting in the third decade of  life and 
predominantly affecting the axial skeleton and large joints. 
This was associated with loss of  function due to pain and 
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stiffness of  the spine which affected his ability to work.
Rheumatoid arthritis (RA) would be consistent with but 
not typical for most of  the presenting features. Notably, 
unlike typical RA, he had asymmetric joint involvement 
and minimal hand involvement. Indeed, he did not meet 
the American College of  Rheumatology diagnostic criteria 
for RA. Other acute inflammatory diseases such as Reiter’s 
syndrome (reactive arthritis) tend not to progress over this 
time frame. Although psoriatic arthropathy can precede 
skin lesions (in approx 6% of  cases)1 and does infrequently 
involve sacroiliac joints, we considered this unlikely due to 
the 7 year history in our patient. Gout may be polyarticular 
but very rarely affects the axial skeleton. Septic arthritis tends 
to be monoarticular, would be more rapidly progressive 
and usually associates with fever. There was no other focus 
of  infection, and infective endocarditis was not clinically 
apparent. Inflammatory bowel disease may cause sacroiliitis 
(particularly Crohn’s disease) which is often independent of  
gastrointestinal symptoms2. However, there was no previous 
history of  gastrointestinal pathology.
Supportive of  our final diagnosis of  ankylosing spondylitis 
(AS) was his age, predominant involvement of  the axial 
skeleton and lumbar radiograph appearance. Additionally, 
although restrictive lung function patterns may in some 
patients reflect interstitial pulmonary fibrosis, the spirometry 
is consistent with reduced chest wall movement. The patient 
met the modified New York criteria for AS. These were 
created to support the clinical diagnosis (see Table 1), and 
avoid earlier problems of  overlap with other seronegative 
spondyloarthropathies3, although the use of  radiological 
features may delay diagnosis4. 
Table 1: Modfied Newyork criteria for AS
Rheumatoid factor would be useful it is positive in three 
quarters of  RA cases, but not in AS. Conversely, HLA-B27 is 
ten times more common in AS then RA5 in US populations. 
These rates may not be correct for our population however; 
ankylosing spondylitis in sub-Saharan Africa presents 
differently, at least in part due to lower prevalence of  the 
HLA-B27 antigen. Such cases are less likely to have an affected 
family member, are milder in severity and have a lower rate 
of  extra-articular features including anterior uveitis6.
The effective management of  AS is multidisciplinary. Where 
possible, rheumatologists, physiotherapists7, and non-
medical support group should be engaged. Other specialty 
consultation is required where complications are suspected. 
These include: uveitis (20-30%); aoritis leading to aortic 
regurgitation (10%); cardiac conduction defects; pulmonary 
fibrosis (particularly of  the upper zones); amyloidosis (with 
potential for renal involvement); osteoporosis and increased 
rates of  bone fracture.
Currently there are no preventive measures or definitive 
treatment for AS. Medical treatment consists of  pain and 
inflammation controllers and disease modifying drugs 
including  tumour necrosis factor alpha (TNFα) blockers. Non-
steroidal anti-inflammatory drugs and opioids are commonly 
used to reduce pain and decrease inflammation. Where 
possible, steroids are not used for long-term management of  
AS because of  the high risk of  adverse effects. Sulfasalazine, 
methotrexate and newer anti-inflammatory drugs are in 
use to modify disease progression. Based on two Cochrane 
systematic reviews, sulfasalazine eases morning stiffness 
but there is no evidence of  benefit on physical function 
or pain8 Methotrexate has little or no benefit9. The TNFα 
antagonists such as etanercept, infliximab and adalimumab 
slow the progress of  AS and in the majority of  clinical cases 
this improves quality of  life by the reduction, though not 
elimination, of  the inflammation and pain. The progression 
of  the disease and the effectiveness of  treatment is monitored 
by serial measurement of  inflammatory markers (such as the 
erythrocyte sedimentation rate [ESR] or C-reactive protein 
[CRP]). 
In this case, methotrexate was initiated as a steroid sparing 
agent as no other appropriate drugs were available. Despite 
this, he presented on a number of  occasions when his 
prednisolone was reduced. He remains on a maintenance 
dose of  10mg/day. Bone protective bisphosphonates are 
unavailable. Presently, there are no overt signs of  Cushing’s 
syndrome and he is able to continue working as a builder.
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